Allarity Therapeutics raises $18.5M, advances lead asset stenoparib, reports early IXEMPRA tumor shrinkage data

Allarity Therapeutics, Inc.

Raised $18.5M in new investment capital since January 2023 to fund clinical programs.
Initiated Phase 1b/2 combination study of stenoparib + dovitinib in early 2023.
IXEMPRA Phase 2 in Europe shows early signs of tumor shrinkage and stable disease in metastatic breast cancer.
Stenoparib is now lead clinical asset; advancing in two of three ongoing trials.
Entered clinical collaboration with FivepHusion for Deflexifol using 5FU-DRP CDx.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Oliver

director

ALLR · Allarity Therapeutics, Inc.

Effective: 2023-08-07
Filed: August 11, 2023, 7:59 PM ET

On August 7, 2023, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) received the resignation of Mr. Robert Oliver as director of the Company, including his position on each Board committee on which he was appointed to, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Oliver resigned as director at Allarity Therapeutics, Inc..

Action: resigned
Role: director

Exact text from the filing

On August 7, 2023, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) received the resignation of Mr. Robert Oliver as director of the Company, including his position on each Board committee on which he was appointed to, effective immediately.

View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-065890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.